Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Arabul, Mahmut; Güllülü, Mustafa; Yılmaz, Yusuf; Akdağ, İ̇brahim; Kahvecioğlu, Serdar; Eren, Mehmet Ali; Dilek, Kamıl

doi:10.1016/j.clinbiochem.2008.05.010

Cited by 27 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results that elevated EPO levels were in large part related to the level of inflammation are in line with the described mechanisms. Interestingly, recent reports demonstrated diminished EPO resistance after statin treatment potentially through pleiotropic "inflammation-lowering" effects (27,28). However, in our study we could not detect any effect of statin treatment on the described associations.…”

Section: Discussioncontrasting

confidence: 56%

Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease

Wagner

Alam

Zimmermann

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryBackground and objectives Anemia and inflammation are prevalent in diabetic patients with chronic kidney disease (CKD). The role of endogenous erythropoietin (EPO) in the pathophysiology of anemia in chronic diseases and its relationship to clinical outcomes remain uncertain. In this cohort study, we aimed to identify factors associated with endogenous EPO levels and investigate their relation to all-cause mortality. Results Patients (median age, 67 years; 52% men; median duration of diabetes, 10 years; median estimated GFR, 49 ml/min per 1.73 m 2 ) were followed for up to 7.0 years. Forty-one patients died. Elevated EPO levels were independently associated with elevated C-reactive protein, low ferritin, and hypertension, in a multivariate model that also included age, cardiovascular disease, kidney function, albumin, cholesterol, and hemoglobin. Higher EPO levels were independently predictive for mortality, as were age, low levels of albumin, and cardiovascular disease. ConclusionsIn diabetic patients with CKD, elevated endogenous EPO levels were predictive for mortality and were related mainly to markers of inflammation, independent of kidney function, and despite low hemoglobin levels. Understanding the phenomenon of EPO resistance and iron dysregulation caused by inflammation is crucial for effective and safe treatment of anemia in patients with CKD.

show abstract

Section: Discussioncontrasting

confidence: 56%

Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease

Wagner

Alam

Zimmermann

et al. 2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…The effects of treatment of 22 dyslipidemic HD patients with renal anemia with 80 mg fluvastatin for 8 weeks on the circulating serum prohepcidin, and high-sensitive C-reactive protein (hs-CRP) levels were compared with placebo. Total cholesterol, LDL-cholesterol, hs-CRP and serum prohepcidin levels significantly decreased with fluvastatin treatment [91] . A cross-sectional study of Suassuna et al evaluated the effects of low doses of simvastatin on inflammatory markers, and hematimetric parameters in patients undergoing hemodialysis [92] .…”

Section: Statinsmentioning

confidence: 97%

Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management

Kanbay¹,

Perazella

Kasapoğlu

et al. 2009

Blood Purif

View full text Add to dashboard Cite

Despite new therapeutic options and treatment strategies, anemia still remains one of the major complications of chronic kidney disease (CKD), especially in patients undergoing chronic hemodialysis for end-stage renal disease. Successful management of anemia is a central part of patient care that may improve clinical outcomes. Although the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) working group reformulated its recommendations by stating that the hemoglobin target in patients receiving erythropoiesis stimulatory agents (ESA) should generally be 11–12 g/dl, this target value can not be achieved in many of them, despite treatment with high doses of ESA. The aim of the present review is to provide an update of the recent literature on causes and possible management of ESA-resistant anemia in CKD patients.

show abstract

“…Therefore, it is possible that statins may also reduce hepcidin levels. This hypothesis is supported by a randomized study of 40 patients with end‐stage renal disease which found that patients assigned to receive fluvastatin had lower serum levels of prohepcidin, a hepcidin precursor, than patients assigned to receive placebo 15 …”

mentioning

confidence: 90%

Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial

Brookhart

Solomon

Glynn

et al. 2011

The Journal of Clinical Pharmacology

View full text Add to dashboard Cite

Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Cited by 27 publications

References 14 publications

Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease

Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease

Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management

Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial

Contact Info

Product

Resources

About